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Abstract
Background: TNF-related apoptosis-inducing ligand (TRAIL) is an immune effector molecule that functions as a selective
anti-tumor agent. However, tumor cells, especially metastatic tumor cells often exhibit a TRAIL-resistant phenotype, which is
currently a major impediment in TRAIL therapy. The aim of this study is to investigate the synergistic effect of TNFa and IFN-
c in sensitizing metastatic colon carcinoma cells to TRAIL-mediated apoptosis.
Methodology/Principal Findings: The efficacy and underlying molecular mechanism of cooperation between TNFa and
IFN-c in sensitizing metastatic colon carcinoma cells to TRAIL-mediated apoptosis were examined. The functional
significance of TNFa- and IFN-c-producing T lymphocyte immunotherapy in combination with TRAIL therapy in suppression
of colon carcinoma metastasis was determined in an experimental metastasis mouse model. We observed that TNFa or IFN-
c alone exhibits minimal sensitization effects, but effectively sensitized metastatic colon carcinoma cells to TRAIL-induced
apoptosis when used in combination. TNFa and IFN-c cooperate to repress Bcl-xL expression, whereas TNFa represses
Survivin expression in the metastatic colon carcinoma cells. Silencing Bcl-xL expression significantly increased the metastatic
colon carcinoma cell sensitivity to TRAIL-induced apoptosis. Conversely, overexpression of Bcl-xL significantly decreased the
tumor cell sensitivity to TRAIL-induced apoptosis. Furthermore, TNFa and IFN-c also synergistically enhanced TRAIL-induced
caspase-8 activation. TNFa and IFN-c was up-regulated in activated primary and tumor-specific T cells. TRAIL was expressed
in tumor-infiltrating immune cells in vivo, and in tumor-specific cytotoxic T lymphocytes (CTL) ex vivo. Consequently, TRAIL
therapy in combination with TNFa/IFN-c-producing CTL adoptive transfer immunotherapy effectively suppressed colon
carcinoma metastasis in vivo.
Conclusions/Significance: TNFa and IFN-c cooperate to overcome TRAIL resistance at least partially through enhancing
caspase 8 activation and repressing Bcl-xL expression. Combined CTL immunotherapy and TRAIL therapy hold great
promise for further development for the treatment of metastatic colorectal cancer.
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Introduction
Recent advance in chemotherapeutic and biological agents for
metastatic colorectal cancer, combined with liver resection, has
dramatically increased the survival of patients with advanced
colorectal cancer [1]. However, metastasis is still the primary cause
of mortality of colorectal cancer patients and there are currently
very limited treatment options for patients with metastatic
colorectal cancer. Therefore, novel therapeutic approaches are
in urgent need. Over the past decade, accumulating experimental
data from both animal models and human patients suggest that the
host immune system functions as an extrinsic tumor suppressor [2]
that might be developed into effective therapies against metastatic
human cancer [3,4]. Molecular analysis of large cohorts of human
colorectal cancers revealed that the level of T lymphocytes and
immune effector molecules in the tumor microenvironment are
positively correlated with the growth, metastasis and recurrence of
human colorectal tumors [5,6,7,8]. Therefore, both immune cells
and immune effector molecules are potentially effective anti-tumor
biologic agents.
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16241TNF-related apoptosis-inducing ligand (TRAIL, also known as
TNFSF10 or APO2L) is expressed on the surface of several subsets
of immune cells. TRAIL activates the extrinsic apoptosis signaling
pathways upon binding to its death domain-containing receptors
and has been under intense study ever since its discovery because it
preferentially induces apoptosis in a wide variety of tumor cells but
not in normal cells [9,10,11]. However, TRAIL only works in
TRAIL-sensitive tumors and most tumor cells often exhibit a
TRAIL-resistance phenotype, which is currently a major obstacle
in TRAIL-based cancer therapy [12,13,14]. To overcome tumor
resistance to TRAIL, various therapeutic agents are used in
combination with recombinant TRAIL or TRAIL receptor
agonist mAbs and have shown to be effective in enhancing
TRAIL efficacy against tumor cells [15,16,17,18,19,20,21,
22,23,24,25,26,27]. In addition to therapeutic agents, immune
modulating cytokine IFN-c has been shown to induce TRAIL
expression in various tissue NK cells and IFN-c-activated TRAIL
plays a significant role in IFN-c-dependent tumor suppression
[28]. Furthermore, IFN-c also regulates the expression of
apoptosis-related genes to overcome tumor cell apoptosis resis-
tance [29,30,31,32,33], suggesting that IFN-c might modulate
both TRAIL expression in immune cells and TRAIL sensitivity in
tumor cells. Recently, it has been shown that TRAIL receptors
and caspase 8 are significantly down-regulated in high grade and
metastatic head and neck squamous cell carcinoma [34],
suggesting that the level of tumor cell resistance to TRAIL might
increase with tumor progression. Indeed, it has been shown that
metastatic human colon carcinoma cells are more resistant to
TARL than the primary colon carcinoma cells [35] and we have
observed that metastatic colon carcinoma cells become resistance
to IFN-c sensitization (Fig. 1). Therefore, IFN-c alone is
insufficient for sensitizing metastatic colon carcinoma cells to
TRAIL-mediated apoptosis (Fig. 1). Because TNFa is also an
inflammatory cytokine that regulates expression of apoptosis
mediators [26,36], we examined whether TNFa could overcome
TRAIL resistance in metastatic colon carcinoma cells. We
observed that TNFa alone exerted minimal sensitization effect
on metastatic colon carcinoma cells. However, when combined
with IFN-c, TNFa dramatically sensitized the metastatic colon
carcinoma cells to TRAIL-induced apoptosis in vitro. Furthermore,
we demonstrated that TRAIL therapy and TNFa/IFN-c-
producing T cell immunotherapy, when used in combination,
can effectively suppress colon carcinoma metastasis in vivo. Thus,
our data revealed a synergistic cooperation between TNFa and
IFN-c in sensitizing metastatic colon carcinoma cells to TRAIL-
mediated apoptosis in vitro and in suppressing colon carcinoma
metastasis in vivo.
Results
TNFa cooperates with IFN-c to sensitize metastatic
human colon carcinoma cells to TRAIL-induced apoptosis
IFN-c has been shown to modulate TRAIL-mediated apoptosis
pathways [32,33]. However, it has recently been shown that
metastatic tumor cells often develop greater degree of TRAIL
resistance [34,35] and we observed that metastatic colon
carcinoma cells are not sensitive to IFN-c sensitization
(Fig. 1A&B). TNFa has been shown to induce TRAIL expression
in breast cancer cells [34]. Therefore, we hypothesized that TNFa
might cooperate with IFN-c to modulate TRAIL-induced
apoptosis in metastatic colon carcinoma cells. To test this
hypothesis, the TRAIL-resistant metastatic human colon carcino-
ma SW620 cells were pre-treated with recombinant TNFa, IFN-c
or both TNFa and IFN-c, and tested their sensitivity to
TRAIL-induced apoptosis. SW620 cells exhibited resistance to
TRAIL treatment (Fig. 1A&B). TNFa or IFN-c pre-treatment
alone did not dramatically increase the tumor cell sensitivity to
TRAIL-induced apoptosis (Fig. 1A&B). However, combined
TNFa and IFN-c pre-treatment significantly increased the tumor
cell sensitivity to TRAIL-induced apoptosis (p,0.01, Fig. 1A&B).
It has been shown that therapeutic agents can sensitize tumor
cells to TRAIL-initiated apoptosis through mediating TRAIL
receptor expression and function [20,37,38,39,40,41,42]. We next
sought to determine whether TNFa and IFN-c regulate TRAIL
receptor expression in SW620 cells. TNFa and IFN-c treatment
exhibited no effect on DR4 and DR5 expression level (Fig. 1C&D).
The decoy receptors T-R3 and T-R4 are undetectable on SW620
cell surface. TNFa and IFN-c treatment did not alter T-R3 and T-
R4 expression (Fig. 1C&D). Therefore, TNFa and IFN-c-
mediated sensitization of colon carcinoma cells to TRAIL-induced
apoptosis does not depend on increasing DR4 and DR5
expression or decreasing T-R3 and T-R4 expression.
TNFa and IFN-c modulate survivin and Bcl-xL expression
in metastatic colon carcinoma cells
Chemotherapeutic sensitization agents have been shown to alter
the expression level of key apoptosis regulators in tumor cells
[21,43,44,45,46,47]. Next, we analyzed the effects of TNFa and
IFN-c on the expression and/or activation of apoptosis mediators.
We observed that TNFa treatment decreased survivin protein
level and combined treatment of TNFa and IFN-c decreased Bcl-
xL protein level in the metastatic SW620 cells (Fig. 2A). The
expression levels of Bcl-2, FLIP, cIAP1 and xIAP were not altered
by TNFa and IFN-c (Fig. 2B). Analysis of mRNA level of survivin
and Bcl-xL revealed that TNFa and/or IFN-c regulate survivin
and Bcl-xL in the gene expression level (Fig. 2A). To determine
whether survivin and Bcl-xL contribute to TRAIL resistance in
SW620 cells, survivin and Bcl-xL were silenced in the tumor cells
by transfection with survivin- and Bcl-xL-specific siRNAs,
respectively. RT-PCR analysis indicated that introduction of
siRNAs dramatically reduced survivin and Bcl-xL expression level
in the tumor cells (Fig. 3A). Silencing Bcl-xL significantly increased
SW620 cell sensitivity to TRAIL-induced apoptosis (Fig. 3B).
However, silencing survivin failed to overcome TRAIL resistance
in SW620 cells (Fig. 3B). To further determine the roles of Bcl-xL
and survivin in TRAIL resistance, SW620 cells were transfected
with Bcl-xL and survivin-expressing plasmid, respectively, and
analyzed their sensitivity to TRAIL-induced apoptosis. Overex-
pression of Bcl-xL significantly decreased TNFa and IFN-c-
sensitized and TRAIL-induced apoptosis in SW620 cells
(Fig. 3C&D). However, although silencing survivin did not alter
the tumor cell sensitivity to TRAIL-induced apoptosis (Fig. 3A&B),
overexpression of survivin also significantly decreased TNFa and
IFN-c-sensitized and TRAIL-induced apoptosis in SW620 cells
(Fig. 3C&D). Taken together, our observations suggest that TNFa
and IFN-c sensitize the metastatic colon carcinoma cells to
TRAIL-induced apoptosis at least partially through repressing Bcl-
xL expression.
Caspase 8 is required for TRAIL-induced apoptosis [48,49],
and it is known that chemotherapeutic agents modulate caspase 8-
dependent and mitochondrion-mediated apoptosis pathway to
sensitize tumor cells to TRAIL-initiated apoptosis [50,51,52]. It is
also known that IFN-c can regulate caspase 8 expression to
mediate apoptosis [29,53]. Therefore, we reasoned that IFN-c
and/or TNFa might also mediate the intrinsic apoptosis pathway
to sensitize colon carcinoma cells to TRAIL-induced apoptosis.
Analysis of SW620 cells revealed that TRAIL induced undetect-
able to weak caspase 8 activation (Fig. 2C). IFN-c or TNFa
TNFa and IFN-c Overcome TRAIL Resistance
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contrast, combined IFN-c and TNFa pre-treatment dramatically
increased TRAIL-induced caspase 8 cleavage in the SW620 cells
as compared to IFN-c or TNFa treatment alone (Fig. 2C).
Consistent with enhanced caspase 8 activation, cytochrome C
release, an activation indicator of the mitochondrion-mediated
apoptosis pathway, and PARP cleavage, a biochemical indicator of
apoptosis, were dramatically increased in IFN-c and TNFa-
pretreated cells after TRAIL treatment (Fig. 2C). Taken together,
our data suggest that IFN-c and TNFa sensitize human colon
carcinoma cells to TRAIL-induced apoptosis also through
modulating caspase 8 activation.
TNFa simultaneously induces NF-kB activation and
TRAIL-mediated apoptosis sensitization
Our above data demonstrated that TNFa, when used in
combination with IFN-c, can sensitize metastatic human colon
carcinoma cells to TRAIL-induced apoptosis. However, TNFa is
also a potent activator of NF-kB [54] and NF-kB has been shown
to play a important role in TRAIL resistance [55,56]. Thus, TNFa
may simultaneously activate apoptosis and cell survival pathways,
two conflicting biological processes, in human colon carcinoma
cells. To determine whether these two conflicting pathways co-
exist and interferes with each other, we examined TNFa-induced
NF-kB activation and the effects of blocking NF-kB activation on
TRAIL-induced apoptosis in human colon carcinoma cell line
SW480. SW480 cell line was chosen since we have a well-
established NF-kB activation model in this cell line. SW480 cells
exhibited spontaneously activated NF-kB activity, albeit at low
level. Treatment of the tumor cells with recombinant TNFa
rapidly and transiently activated NF-kB (Fig. 4A). Although IFN-c
cooperates with TNFa to enhance TRAIL-induced apoptosis,
IFN-c did not alter TNFa-mediated NF-kB activation (Fig. 4A). It
has been shown that it is IKKb that activate the canonical NF-kB
to promote tumor [57]. Next, we stably transfected SW480 cells
with empty vector (SW480.Vector) and a vector expressing IKKb
mutant IKKb-K44A (SW480.IKKb-KA) [58], and examined the
effects of inhibition of NF-kB activation on colon carcinoma cell
sensitivity to TRAIL. EMSA analysis indicated that ectopic
expression of the IKKb mutant blocked both constitutively and
TNFa-induced NF-kB activation (Fig. 4A).
SW480.IKKb-KA cells exhibited a slight increase in sensitivity
to TRAIL-induced cell death than SW480.Vector cells under our
culture conditions (approximately 1.4% more) (Fig. 4B&C).
However, the TRAIL-induced cell death in IFN-c, TNFa and
both IFN-c and TNFa treatment groups of SW480.IKKb-KA
cells is significantly higher as compared to those in of
SW480.Vector cells (Fig. 4B&C), suggesting that TNFa-activated
NF-kB does interfere with TNFa-sensitized apoptosis. Neverthe-
less, TNFa-mediated apoptosis sensitization function apparently
Figure 1. TNFa cooperates with IFN-c to sensitize human colon carcinoma cells to TRAIL-induced apoptosis. A. TRAIL-induced
apoptosis. TRAIL-resistant SW620 cells were either untreated (control), treated with IFN-c (100 U/ml), TNFa (100 U/ml), or both IFN-c and TNFa
overnight, followed by incubation with recombinant TRAIL (100 ng/ml). Cell death was analyzed by PI staining and flow cytometry analysis.
B. Percent TRAIL-induced cell death was calculated as % PI-positive cells in the presence of TRAIL (+TRAIL) - % PI positive in the absence of TRAIL
(-TRAIL). Column: mean, bar: SD. C&D. Expression level of cell surface TRAIL receptors. SW620 cells were treated with IFN-c, TNFa, or both IFN-c and
TNFa for approximately 24 h and stained with the receptor-specific antibodies, respectively. The stained cells were then analyzed with flow
cytometry. Isotype-matched IgG control staining is depicted as gray areas, and DR4-, DR5-, T-R3- and T-R4-specific staining is depicted as solid lines.
The mean fluorescent intensity (MFI) of DR4 and DR5 are quantified (D). Column: mean, bar: SD.
doi:10.1371/journal.pone.0016241.g001
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effect to result in an overall apoptosis sensitive phenotype in
human colon carcinoma. Our data thus suggest that blocking NF-
kB activity might increase human colon carcinoma cells to IFN-c/
TNFa-sensitized and TRAIL-induced apoptosis.
TRAIL plays a significant role in immune cell-mediated
colon carcinoma rejection
To translate the above findings to TRAIL-based therapy
against colon carcinoma metastasis, we next examine the
function of TRAIL in suppression of colon carcinoma in
preclinical mouse models. Because immune cells express TRAIL
[28,59,60], we used mouse colon carcinoma model [55] to
determine whether colon carcinoma cell-activated immune cells
express TRAIL. Mouse colon carcinoma CT26 cells were
transplanted to BALB/c mice to develop lung metastases.
Approximately 21 days after tumor transplant, tumor-bearing
lungs were excised to make single cell suspension. Infiltrating
immune cells were identified in the tumor-bearing lungs (Fig. 5A).
Macrophage consists of the largest population of tumor
infiltrating immune cells (3.45%), followed by NK cells
Figure 2. TNFa and IFN-c repress survivin and Bcl-xL expres-
sion in metastatic colon carcinoma cells. A. Analysis of survivin
and Bcl-xL protein and mRNA level. SW620 cells were treated with
IFN-c, TNFa or both IFN-c and TNFa for 24 h. Cells were then
analyzed by Western blotting analysis (top panel) for the level of the
indicated proteins and by RT-PCR analysis (bottom panel) for mRNA
level of the indicated genes. B. Analysis of protein levels of anti-
apoptotic genes. Cells were treated as described in A and analyzed
by Western blotting analysis for the indicated proteins. C. Caspase
activation and apoptosis. SW620 cells were treated with IFN-c, TNFa
or both IFN-c and TNFa overnight, followed by incubation with
recombinant TRAIL protein (100 ng/ml) for the indicated time. Total
cell lysates were then prepared and analyzed by Western blotting for
activated caspase 8. Cytosol fractions were also prepared from cells
as treated above and analyzed for cytochrome C release and PARP
cleavage.
doi:10.1371/journal.pone.0016241.g002
Figure 3. Bcl-xL mediates TRAIL resistance in the metastatic
colon carcinoma cells. A. Silencing Bcl-xL and survivin expression by
siRNAs. SW620 cells were transiently transfected with scramble or gene-
specific siRNAs for approximately 20 h and analyzed for Bcl-xL and
Survivin mRNA level by RT-PCR. B. Silencing Bcl-xL but not survivin
expression significantly increased the tumor cell sensitivity to TRAIL-
induced apoptosis. The scramble and gene-specific siRNA-transfected
cells were cultured in the absence or presence of TRAIL protein for
approximately 24 h and analyzed for apoptosis. ** p,0.01.
C. Overexpression of Bcl-xL and Survivin decreased the tumor cell
sensitivity to TRAIL-induced apoptosis. SW620 cells were transiently
transfected with Vector control (Vector), Bcl-xL-expressing (Bcl-xL) or
Survivin-expressing (Survivin) plasmids for approximately 20 h. The cells
were then analyzed for Bcl-xL and Survivin mRNA level by RT-PCR (left
panel). The cells were also treated with IFN-c and TNFa for 4 h, followed
by incubation with TRAIL protein for approximately 24 h and analysis
for apoptosis by PI staining and flow cytometry analysis (right panel).
** p,0.01.
doi:10.1371/journal.pone.0016241.g003
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+ T cells (1.08%) and CD4
+ T cells (0.23%). Flow
cytometry analysis revealed that 79-96% of these infiltrating
immune cells express TRAIL protein on their surface (Fig. 5A).
RT-PCR analysis confirmed that TRAIL is expressed in these
four subsets of tumor-infiltrating immune cells (Fig. 5B). To
validate TRAIL expression in immune cells in a more defined
system, we then stained TRAIL protein in a CT26 tumor-
specific cytotoxic T lymphocyte (CTL) line. The CTLs were
stimulated with irradiated tumor cells and analyzed for TRAIL
protein level on the cell surface. It is clear that these tumor-
specific CTLs express high level of TRAIL (Fig. 5C).
To determine whether TRAIL plays a significant role in tumor
rejection, CT26 cells were mixed with IgG control mAb and
TRAIL neutralizing mAb, respectively, and injected to syngeneic
mice. Analysis of lung metastasis revealed that blocking TRAIL
function significantly increased CT26 tumor cell metastasis rate
(p,0.001)(Fig. 5D). In summary, our data suggest that TRAIL
protein is expressed in tumor-infiltrating immune cells and plays a
Figure 4. TNFa-mediated NF-kB activation on TRAIL-induced apoptosis. A.A n a l y s i so fI K K b-KA-mediated inhibition of NF-kB activation.
Left panel: TNFa-induced NF-kB activation kinetics. SW480 cells were treated with TNFa for the indicated time. Nuclear extracts were prepared
a n du s e di nt h eE M S Au s i n gad o u b l e - s t r a n d e do l i g on u c l e o t i d ep r o b ec o n t a i n i n gN F - kB consensus sequence. Middle panel: specificity of NF-kB
EMSA. SW480 cells were treated with IFN-c,T N F a or both IFN-c and TNFa f o r6 0m i na n da n a l y z e df o rN F - kB activation by EMSA. IgG (lane 4),
anti-p50 subunit of NF-kB antibody (lane 5), and excess molar ratio of cold probe (lane 6) were used for the specificity assay. Right panel:
inhibition of NF-kB activation by IKKb-KA mutant. SW480.Vector and SW480.IKKb-KA cells were treated with IFN-c,T N F a or both IFN-c and TNFa
f o r6 0m i na n du s e di nt h eE M S Aa s s a ya ss h o w na b o v e .B. Sensitivity of SW480.Vector and SW480.IKKb-KA cells to TRAIL-induced apoptosis.
Tumor cells were treated with IFN-c,T N F a,o rb o t hI F N - c and TNFa overnight, followed by incubation with recombinant TRAIL for approximately
24 h. Cells were then stained with PI and analyzed for cell death. C. Quantification of TRAIL-induced cell death. Cell death as shown in B was
quantified.
doi:10.1371/journal.pone.0016241.g004
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carcinoma metastasis.
Level of tumor infiltrating CD8
+ T cells inversely
correlates with tumor progression stage
Our above observations suggest that both tumor-infiltrating
CD8
+ T cells and in vitro activated CD8
+ T cells express TRAIL
(Fig. 5). We next analyzed T cell infiltration in human colorectal
cancer specimens using a colorectal cancer progression tissue
microarray (TMA) and observed that CD8
+ T cells are present in
all 14 adenoma specimens examined with an average of 79 cells
per section (Fig. 6A, a&b). The average CD8
+ T cell number is 37
per section in the adenocarcinoma (Fig. 6A, c&d). Six of the 7
distal metastases specimens (4 liver metastases and 3 lung
metastases) exhibited few than 22 CD8
+ T cells per section
(Fig. 6A, e), whereas one of the 7 metastases specimens (lung
metastases) has 125 CD8
+ T cells per section (Fig. 6B). Post hoc
pair-wise comparisons showed that the adenoma has significantly
higher mean CD8
+ T cells than adenocarcinoma (p=0.0051) and
Liver/Lung metastases (p=0.0036). Although most of the
adenocarcinoma specimens have more CD8
+ T cells than the
liver/lung metastases (37 vs 26), no statistically significant
difference was found between adenocarcinoma and the liver/lung
metastases (p=0.4957), probably due to the higher CD8
+ T cell
number in one of the lung metastases specimen (Fig. 6B).
CTL adoptive immunotherapy in combination of TRAIL
therapy effectively suppresses colon carcinoma
metastasis
Our data suggest that IFN-c and TNFa when used in
combination, are effective sensitizers for TRAIL-induced apoptosis
in metastatic colon carcinoma cells (Fig. 1), however, system
infusion of exogenous IFN-c or TNFa are often highly toxic to the
host [36], thereby limiting their clinical use. CD8
+ T cells rapidly
up-regulate IFN-c and TNFa expression upon activation (Fig. 7A),
therefore, the locally produced IFN-c and TNFa in the tumor
microenvironment by tumor-infiltrating T cells should be non-toxic
and yet effective sensitizers in TRAIL therapy. Because CD8
+ T
cells also express TRAIL (Fig. 5C), the function of tumor-specific
CD8
+ T cells can be two folds: first, CD8
+ T cells may infiltrate
inside tumor (Fig. 6Aa b&d) and utilize IFN-c, TNFa and TRAIL
to induce tumor cell apoptosis; second, CD8
+ T cells may not
effectively infiltrate the advanced tumor, especially the metastatic
tumor (Fig. 6A, c&e), however, the activated CD8
+ T cells can still
secrete IFN-c and TNFa.I F N - c and TNFa may move inside the
tumor through peripheral blood circulation to sensitize the tumor
cells. In that case, exogenous TRAIL may be applied to treat the
TRAIL-resistant cancer. To test this hypothesis, we first sought to
determine whether TRAIL plays a significant role in CTL-
mediated suppression of colon carcinoma metastasis. CT26 cells
were transplanted to syngeneic mice to establish lung metastases.
Five days later, tumor-specific and perforin-deficient pfpCTLs were
incubated with IgG control mAb and TRAIL neutralizing mAb,
respectively, and adoptively transferred to the tumor-bearing mice.
The CT26 cells are Fas-resistant. Use of perforin-deficient pfpCTLs
and Fas-resistant CT26 tumor cells will eliminate the function of
perforin and Fas/FasL effector mechanisms of the CTLs, thus
reducing the CTL cytotoxicity background for optimal TRAIL
function evaluation. It is clear that blocking TRAIL function
significantly decreased CTL-mediated tumor rejection efficacy
(p=0.03)(Fig. 7B), suggesting that tumor-specific CTLs at least
partially use TRAIL to suppress colon carcinoma development in
vivo.
Figure 5. TRAIL expression and function in tumor-infiltrating immune cells. A. Tumor-bearing lungs were excised approximately 21 days
after tumor cell injection and analyzed by flow cytometry. The percentage of CD4
+ Tc e l l s ,C D 8
+ T cells, CD11b
+ macrophages and NK cells in the tumor
populationwere gated for TRAIL expressionanalysis. The percentage ofTRAIL-positive cells in eachsubset of immune cells as shown in A were quantified
and expressed as mean 6 SD. B. TRAIL mRNA level in tumor-infiltrating immune cells. CD4
+ Tc e l l s ,C D 8
+ T cells, CD11b
+ macrophage and NK cells were
purifiedfromthe singlecell suspensionusingcell type-specific mAband magnet beads andanalyzedforTRAIL transcriptlevelbyRT-PCR.Datafrom three
mice are shown. C. Cell surface TRAIL protein level in tumor-specific CTLs. CTLs were stained with fluorescent dye-conjugated anti-TRAIL mAb and
analyzedbyflowcytometry.Isotype-matchedIgGcontrolstainingisdepictedasgray area,andTRAIL-specificstainingisdepictedassolidline.D.Fu nc ti on
of TRAIL in suppression of colon carcinoma. CT26 cells (5610
4 cells/mouse) were mixed with IgG and anti-TRAIL neutralizing mAbs (50 mg/mouse),
respectively, and injected into mice i.v. Two days later, IgG or anti-TRAIL mAb (100 mg/mouse) were injected into miceagain. Mice were sacrificed 14 days
after tumor transplantation and analyzed for lung metastasis. Images oflungs from representativemice are shown (toppanel). Thenumber oflungtumor
nodules was enumerated in a single-blinded fashion. Each dot represents total counts from independent mice (bottom panel). Counts greater than 250
are expressed as $250. The difference between the IgG control and the anti-TRAIL mAb treatment group is statistically significant (p,0.01).
doi:10.1371/journal.pone.0016241.g005
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whether combined therapy of TRAIL and CTL adoptive transfer
is more effective in suppressing established lung metastases than
single agent therapy. CT26 cells were transplanted to syngeneic
mice for 5 days to establish extensive lung metastases. pfpCTL and
TRAIL protein were then injected to the tumor-bearing mice
either alone or in combination. The prediction is that if CTLs
indeed can secrete IFN-c and TNFa to sensitize the tumor cells,
then combinational therapy of CTL adoptive transfer and TRAIL
therapy should exhibit greater anti-tumor efficacy than CTL or
TRAIL alone. Indeed, TRAIL therapy alone exhibit no significant
efficacy against the TRAIL-resistant CT26 colon carcinoma
(p=0.15). Although pfpCTL alone showed a significantly anti-
tumor cytotoxicity (p,0.001), combinational therapy of CTLs and
TRAIL exhibits significantly greater tumor rejection efficacy
against the established colon carcinoma lung metastases than CTL
alone (p,0.001)(Fig. 7C). In summary, our data suggest that
TRAIL therapy alone is ineffective in suppressing TRAIL-resistant
colon carcinoma in vivo. Combined TRAIL therapy and CTL
adoptive transfer immunotherapy is significantly more effective
than CTL adoptive immunotherapy alone for the treatment of
metastatic colon cancer.
Discussion
We demonstrated here that combined treatment of TNFa and
IFN-c, two physiologic cytokines of the host immune system,
effectively sensitized metastatic human colon carcinoma cells to
TRAIL-induced apoptosis (Fig. 1). Therefore, TNFa and IFN-c is
a pair of sensitizers that can effectively overcome TRAIL
resistance in metastatic colon carcinoma cells.
The molecular mechanisms underlying TRAIL resistance in
tumor cells have been an active research area. It has been shown
that decreased TRAIL receptor level or increased decoy TRAIL
receptor level can lead to enhanced TRAIL resistance [12].
Similarly, the altered expression of anti-apoptotic Bcl-2 family
proteins can confer the tumor cells with TRAIL resistance
[12,21,24,44,45,46,61,62,63]. It has also been shown that anti-
apoptotic protein survivin is highly expressed in colon carcinoma
cells [64,65]. These observations suggest that TRAIL resistance
mechanisms might be tumor type and stage-dependent. In this
study, we found that TNFa decreased the expression level of
survivin (Fig. 2A). However, although survivin is a protein that
inhibits apoptosis and promote cell survival [66], silencing survivin
failed to overcome TRAIL resistance in metastatic colon
Figure 6. Tumor-infiltrating CD8
+ T cells in human colon carcinoma. A. Immunohistochemical staining of CD8
+ T cells in human colon cancer
specimens. CD8 immunoreactivity is shown as the brown-stained cells, whereas cells that are unreactive are indicated by the blue counterstain.
Shown are representative images. a&b: adenoma; c&d: adenocarcinoma; e: liver metastases. B. Quantification of the number of CD8
+ T cells in the
colon cancer specimens. The number of CD8
+ T cells in each specimen printed on the TMA as shown in A was counted. Each dot represents the
average number of CD8
+ T cells of three sections of the same tumor specimen (left panel). The mean CD8
+ T cell number are: adenoma: 79.4,
adenocarcinoma: 37.45, and liver/lung metastases: 25.69. Right panel: Statistical analysis of CD8
+ T cells between different stages of tumors. One-way
analysis of variance was used with a Bonferroni multiple comparison procedure to test for pair-wise post hoc differences between the three types of
tumor specimens. Adenoma has a significantly higher mean CD8
+ T cells than adenocarcinoma (p=0.0051) and liver/lung metastases (p=0.0036).
Adenocarcinoma was not significantly different than liver/lung metastases in mean CD8
+ T cells (p=0.4957).
doi:10.1371/journal.pone.0016241.g006
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determinant of TRAIL resistance in the metastatic colon
carcinoma cells. Indeed, silencing Bcl-xL expression significantly
increased the tumor cell sensitivity to TRAIL-induced apoptosis
and overexpression of Bcl-xL significantly decreased the tumor cell
sensitivity to TNFa and IFN-c-sensitized and TRAIL-induced
apoptosis. Therefore, it seems that Bcl-xL is at least partially
responsible for TRAIL resistance in the metastatic colon
carcinoma cells. In addition, we observed that TNFa and IFN-c
cooperatively enhance TRAIL-induced caspase 8 activation
(Fig. 2C). It is known that enhanced caspase 8 recruitment to
the DISC is essential for overcoming TRAIL resistance in human
hepatocellular carcinoma cells [49], therefore it is possible that
TNFa and IFN-c may enhance caspase 8 association with the
DISC or mediate DISC conformation to alter the caspase 8
cleavage kinetics in human colon carcinoma cells, which remains
to be determined.
TNFa is a potent inducer of NF-kB activation [55,67].
Exposure of human colon carcinoma cells to TNFa rapidly
activated NF-kB (Fig. 4A), and blocking NF-kB activation
significantly increased human colon carcinoma cells to TRAIL-
induced apoptosis (Fig. 4B), suggesting that NF-kB does
counteract with TRAIL-induced apoptosis. However, even though
TNFa induces NF-kB activation, TNFa functions primarily as a
sensitizer of TRAIL-induced apoptosis and it seems that TNFa-
mediated apoptosis sensitization function apparently overpowers
the TNFa-induced and NF-kB-mediated tumor cell survival
effects. In the literature, it has been shown that NF-kB activation
promotes inflammation-mediated tumor cell survival and progres-
sion [54] and blocking NF-kB activation can convert inflamma-
tion-induced tumor progression mediated by TNFa to TRAIL-
mediated tumor regression in an experimental metastasis mouse
model [55]. It is very likely that blocking NF-kB activation might
enhance tumor cell sensitivity to TRAIL-induced apoptosis [56]
and inhibit inflammation-mediated tumor promotion in the tumor
microenvironment, thus enhancing TNFa function in sensitization
of metastatic colon carcinoma cells in TRAIL therapy, which
requires further study.
The major subsets of immune cells, including T cells, NK cells
and myeloid cells, all express TRAIL (Fig. 5) and activated T cells
produce IFN-c and TNFa (Fig. 7). Therefore, IFN-c, TNFa and
TRAIL of these immune cells may cooperate to effectively induce
tumor cell apoptosis when infiltrated into tumor. However, as
demonstrated in this study and reported in the literature, the
Figure 7. Combined TRAIL therapy and CTL adoptive immunotherapy effectively suppressed colon carcinoma metastasis. A. IFN-c
and TNFa expression in activated CD8
+ T cells. Primary CD8
+ T cells were purified from spleens of naı ¨ve mice and stimulated with anti-CD3 and CD28
mAbs for 3 and 24 h, respectively. The tumor-specific CD8
+ T cells were stimulated with irradiated tumor cells for 3 and 24 h, respectively. The un-
stimulated and stimulated cells were then analyzed for IFN-c and TNFa mRNA level by RT-PCR. B. Function of TRAIL in CTL-mediated tumor rejection.
CT26 cells (1610
5 cells/mouse) were injected into mice. Five days later, perforin-deficient CTLs (pfp CTL, 1610
6 cells/mouse) were mixed with IgG or
TRAIL neutralizing mAb (50 mg/mouse) and injected into the tumor-bearing mice. IgG and TRAIL neutralizing mAb (100 mg/mouse) were injected
again into the tumor-bearing mice 2 days later. Mice were sacrificed 14 days after CTL treatment and analyzed for lung metastasis. Images of lungs
from representative mice are shown. The number of lung tumor nodules was enumerated in a single-blinded fashion. Each dot represents total tumor
counts from a single mouse. The difference between CTL+IgG control group and CTL+Anti-TRAIL mAb group is statistically significant (p=0.03). C.
Combined TRAIL and CTL adoptive immunotherapy effectively suppressed colon carcinoma metastasis. CT26 cells (1610
5 cells/mouse) were injected
into mice. Five days later, pfp CTLs (1610
6 cells/mouse), TRAIL (200 mg/mouse), or both pfpCTL and TRAIL were injected into the tumor-bearing mice.
Mice groups that received TRAIL or both pfpCTL and TRAIL were injected with TRAIL (200 mg/mouse) again every 2 days for 4 more times. Mice were
sacrificed 16 days after tumor transplantation and analyzed for lung metastasis. The number of lung tumor nodules was enumerated in a single-
blinded fashion. Each dot represents total counts from a single mouse. Counts greater than 250 are expressed as $250. The difference between
control and TRAIL treatment group is not statistically significant (p=0.15). The differences between control and pfpCTL treatment alone group and
between control and pfpCTL+TRAIL treatment group are both statistically significant (p,0.001).
doi:10.1371/journal.pone.0016241.g007
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+ T cells) are frequently
unable to infiltrate the colorectal tumor, especially metastatic
colorectal carcinoma (Fig. 6). Because TRAIL needs to directly
contact the TRAIL receptors on the tumor cell surface to induce
apoptosis, lack of infiltration of immune cells into the tumor may
result in lack of TRAIL-induced apoptosis of the tumor cells. IFN-
c, TNFa and TRAIL are soluble molecules and thus should be
able to penetrate into the tumor through the blood circulation.
However, systemic use of IFN-c and TNFa is highly toxic.
Therefore, we reasoned that use of adoptive transfer of tumor-
specific CTLs to produce IFN-c and TNFa locally in the tumor
microenvironment in combination with TRAIL protein/mAb
therapy should effectively induce colon carcinoma cell apoptosis,
and thereby suppressing colon cancer metastasis. In our prove of
concept study, we demonstrated that tumor-specific CTL adoptive
transfer immunotherapy, when combined with TRAIL therapy,
achieved significantly greater metastasis suppression efficacy
against the TRAIL-resistant colon carcinoma than either therapy
alone (Fig. 7C). Taken together, our results suggest that combined
CTL immunotherapy and TRAIL therapy hold great promise for
further development for the treatment of metastatic colon cancer.
Materials and Methods
Mice
Mice were purchased from the National Cancer Institute
(Frederick, MD) and housed in the Medical College of Georgia
animal facility. All Experiments with mice and care/welfare for
mice used in this study were in agreement with National Institutes
of Health regulations and were carried out with a protocol
(Protocol # 05-12-728*B) approved by the Medical College of
Georgia Institute Animal Care and Use Committee.
Tumor cells and specimens
All colon carcinoma cell lines were obtained from ATCC
(Manassas, VA). De-identified human colon carcinoma specimens
were provided by the Cooperative Human Tissue Network
(CHTN) sponsored by the National Cancer Institute. All studies
with human tumor specimens were carried out in accordance with
NIH and MCG guidelines.
Measurement of TRAIL-induced apoptosis
Recombinant TRAIL protein was expressed and purified as
described [68]. Cell death was measured by Propidium Iodide (PI,
Trevigen Inc. Gaithersburg, MD) staining and flow cytometry
analysis as described [68]. IFN-c and TNFa were obtained from
R&D System (R&D Systems, Minneapolis, MN).
Cell surface marker analysis
Tumor cells were stained with anti-TRAIL receptor DR4, DR5,
T-R3 and T-R4 mAb or an isotype-matched control IgG (Alexis
Biochemicals, San Diego, CA). Immune cell were stained with
CD4-, CD8-, CD11b-, and NK1.1-specific mAbs (Pharmingen)
and PE-TRAIL mAb (Biolegend. San Diego, CA). The stained
cells were analyzed with flow cytometry.
Western Blot Analysis
Total cell lysates and cytosol fractions were prepared and
analyzed by Western blotting analysis as previously described [68].
The antibodies used in this study are as follows: Bcl-x (BD
Biosciences. Cat #610747) at 1:250, Bcl-2 (BD Biosciences. Cat#
610539) at 1:250, Caspase 8 (R&D System. Cat#AF1650) at
0.5 mg/ml. cIAP1 (Santa Cruz. Cat# sc-7943) at 1:100,
Cytochrome C (BD Biosciences. Cat# 556433) at 1:1000, FLIP
(Cell Signaling. Cat# 3210) at 1:200, PARP (Cell Signaling. Cat#
9544) at 1:1000, Survivin (Santa Cruz Biotech. Cat# sc-17779) at
1:100, xIAP (Cell Signaling. Cat# 2042) at 1:500, and b-actin
(Sigma. Cat# A5441) at 1:8000.
Electrophoresis Mobility Shift Assay (EMSA) of NF-kB
activation
NF-kB activation was analyzed using EMSA with NF-kB probe
(AGT TGA GGG GAC TTT CCC AGG C, Santa Cruz Biotech)
as previously described [69]. Briefly, the end-labeled probes were
incubated with nuclear extracts for 20 min at room temperature.
For specificity controls, unlabeled probe was added to the reaction
at a 1:100 molar excess. Anti-p50 subunit antibody (Santa Cruz
Biotech) was also included to identify NF-kB-specific DNA
binding. DNA-protein complexes were separated by electropho-
resis in 6% polyacrylamide gels and identified using a phospho-
image screen (Molecular Dynamics) and the images were acquired
using a Strom 860 imager (Molecular Dynamics).
RT-PCR analysis
Total RNA was isolated from cells or tissues using Trizol
(Invitrogen, San Diego, CA) and used for RT-PCR analysis of
gene expression as described [70]. The primer sequences are as
follows: Mouse IFN-c: forward: 59-ATGGCTGTTTCTGG-
CTGTTACTG-39, reverse: 59-GCTTCCTGAGGCTGGATTC-
C-39. Mouse TNFa: forward: 59-TGACAAGCCTGTAGCCC-
ACG-39, reverse: 59-GACTCCAAAGTAGACCTGCCCG-39.
Mouse Bcl-xL: forward: 59-CATGGCAGCAGTAAAGCAAGC-
39, reverse: 59-GCATTGTTCCCATAGAGTTCC-39. Survivin:
forward: 59-AGGACCACCGCATCTCTAC-39, reverse: 59-AC-
TTTCTTCGCAGTTTCCTC-39. b-actin: forward: 59-ATTGT-
TACCAACTGGGACGACATG-39, reverse: 59-CTTCATGAG-
GTAGTCTGTCAGGTC-39.
Gene silencing
Scramble siRNA (UAGCGACUAAACACAUCAAUU) was
obtained from Dharmacon Inc. Bcl-xL-specific siRNA (Cat #
sc-43630) and Survivin-specific siRNA (Cat# sc-29499) were
obtained from Santa Cruz Biotech. Tumor cells were transfected
with the scramble and gene-specific siRNAs, respectively, using
lipofectamine 2000 (Invitrogen Inc.) according to the manufac-
turer’s instructions.
Tumor cell transfection
Bcl-xL plasmid (pSFFV-neo.Bcl-xL) [71] was obtained from
Addgene. Survivin plasmid [64] was kindly provided by Dr.
Michael Brattain (University of Nebraska Medical Center). Tumor
cells were transient transfected with the vector control plasmid,
Bcl-xL- or Survivin-expressing plasmid, respectively, using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Tumor cells were harvested approximately 20 h after
transfection and used for the indicated studies.
Immunohistochemistry
Immunohistochemical staining was as previously described [72]
using CD8 antibody (DAKO Corp) at 1:250 dilution. Slides were
counterstained with hematoxylin (Richard-Allan Scientific, Kala-
mazoo, MI).
Analysis of tumor-infiltrating immune cells
To purify subsets of tumor-infiltrating immune cells, tumor cell
digests were incubated with CD8-conjugated Dynal bead
(Invitrogen), CD4, CD11b and NK1.1 mAbs (Biolegend) respec-
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then incubated with BioMag anti-mouse/rat IgG (Polysciences
Inc. Warrington, PA). The bead-bound cells were then separated
by magnetic separation and lysed immediately in Trizol buffer
(Invitrogen) for RNA isolation.
Experimental lung metastasis mouse model and CTL
immunotherapy
Tumor-specific CTLs were generated from perforin-deficient
BALB/c mice as previously described [73]. The experimental lung
metastasis mouse model and CTL adoptive transfer immunother-
apy was carried out as previously described [73].
Statistical Analysis
All statistical analyses for T cell infiltration in the tumor
specimens were performed using SAS 9.2. A one-way analysis of
variance (ANOVA) and a Tukey-Kramer multiple comparison
procedure was performed to analyze correlation between receptor
level and apoptosis rate.
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